Company: CERO
Filing Date: 2025-09-04
Form Type: 424B3
Source: 0001213900-25-084610
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-04
Form: 424B3
Chunk 2
---
ement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                         |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share                                                   |     | CERO              |     | NASDAQ Capital Market                     |
| Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 28, 2025, CERo
Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter from the staff at the
Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the
minimum stockholders’ equity requirement of $2,500,000 (the “Stockholders’ Equity Requirement”)
for continued listing on the Nasdaq Capital Market (“Nasdaq”) set forth in Nasdaq Rule 5550(b).

As previously disclosed,
the Company previously had been out of compliance with Nasdaq continued listing requirements until, on May 7, 2025, the Company received
a determination of a Nasdaq hearings panel (a “Hearings Panel”) that it had regained compliance with such requirements.
Pursuant to Nasdaq Rule 5815(d)(4)(B), the Company is subject to a mandatory hearings panel monitor until one year after regaining compliance
with such requirements. As a result, Nasdaq